Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 5(5): e10476, 2010 May 04.
Article in English | MEDLINE | ID: mdl-20454563

ABSTRACT

Powering future generations of implanted medical devices will require cumbersome transcutaneous energy transfer or harvesting energy from the human body. No functional solution that harvests power from the body is currently available, despite attempts to use the Seebeck thermoelectric effect, vibrations or body movements. Glucose fuel cells appear more promising, since they produce electrical energy from glucose and dioxygen, two substrates present in physiological fluids. The most powerful ones, Glucose BioFuel Cells (GBFCs), are based on enzymes electrically wired by redox mediators. However, GBFCs cannot be implanted in animals, mainly because the enzymes they rely on either require low pH or are inhibited by chloride or urate anions, present in the Extra Cellular Fluid (ECF). Here we present the first functional implantable GBFC, working in the retroperitoneal space of freely moving rats. The breakthrough relies on the design of a new family of GBFCs, characterized by an innovative and simple mechanical confinement of various enzymes and redox mediators: enzymes are no longer covalently bound to the surface of the electron collectors, which enables use of a wide variety of enzymes and redox mediators, augments the quantity of active enzymes, and simplifies GBFC construction. Our most efficient GBFC was based on composite graphite discs containing glucose oxidase and ubiquinone at the anode, polyphenol oxidase (PPO) and quinone at the cathode. PPO reduces dioxygen into water, at pH 7 and in the presence of chloride ions and urates at physiological concentrations. This GBFC, with electrodes of 0.133 mL, produced a peak specific power of 24.4 microW mL(-1), which is better than pacemakers' requirements and paves the way for the development of a new generation of implantable artificial organs, covering a wide range of medical applications.


Subject(s)
Bioelectric Energy Sources , Glucose/metabolism , Implants, Experimental , Animals , Catechol Oxidase/metabolism , Electrodes , Glucose Oxidase/metabolism , Hydrogen-Ion Concentration , Male , Oxidation-Reduction , Prosthesis Implantation , Rats , Rats, Wistar , Time Factors , Ubiquinone/metabolism , Urea/metabolism , Urease/metabolism
2.
Dalton Trans ; (43): 5911-21, 2008 Nov 21.
Article in English | MEDLINE | ID: mdl-19082047

ABSTRACT

A series of new mononuclear and dinuclear platinum(ii) compounds based on two bipyridyl systems, linked by an alkyl chain {1,2-bis[4-(4'-methyl-2,2'-bipyridinyl)]ethane, L2, (a), and 1,6-bis[4-(4'-methyl-2,2'-bipyridinyl)]hexane, L6, (b)} have been synthesized and characterized by IR and multinuclear and multidimensional NMR spectroscopy. The coordination sphere of the complexes, designed to give intercalating and/or covalent interactions with DNA, is completed only by exchangeable (Cl(-), I(-) or H(2)O) and/or not leaving (chelate ethylenediamine, en) saturating ligands. Quenching of the DNA-ethidium fluorescence was performed in order to verify the intercalating capability of the water soluble compounds. Furthermore, the in vitro cytotoxicity of all water soluble complexes has been assessed with respect to cisplatin on platinum-sensitive human endometrium (HeLa) and platinum-resistant human breast (MCF-7) cancer cell lines.


Subject(s)
Chelating Agents/chemical synthesis , Chelating Agents/toxicity , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/toxicity , Nitrogen/chemistry , Platinum Compounds/chemical synthesis , Platinum Compounds/toxicity , Cell Line, Tumor , Cell Survival/drug effects , Chelating Agents/chemistry , Heterocyclic Compounds/chemistry , Humans , Ligands , Magnetic Resonance Spectroscopy , Molecular Structure , Platinum Compounds/chemistry
3.
Inorg Chem ; 46(9): 3714-25, 2007 Apr 30.
Article in English | MEDLINE | ID: mdl-17411031

ABSTRACT

The crystal and molecular structure and the stability of lead and calcium complexes of two chelates containing picolinate chelating groups in different geometries have been investigated in order to relate the ligand affinity and selectivity for lead over calcium with the ability of the ligand to accommodate a stereochemically active lone pair. The crystal structures of the lead complexes of the diprotonated and monoprotonated tripodal ligand tpaa2- show that the three picolinate arms of the tripodal ligand coordinate the lead in an asymmetric way leaving a gap in the coordination sphere to accommodate the lead lone pair. As a consequence of this binding mode, one picolinate arm is very weakly bound and therefore can be expected to contribute very little to the complex stability. Conversely, the geometry of the dipodal ligand H2dpaea is designed to accommodate the lead lone pair; in the structure of the [Pb(dpaea)] complex the donor atoms of the ligand occupy only a quarter of the coordination sphere, reducing the sterical interaction between the lead lone pair with respect to the H3tpaa complexes. As a result, in the lead structures of H2dpaea all the ligand donor atoms are strongly bound to the metal ion leading to increased stability. The high value of the formation constant measured for the lead complex of the dipodal dpaea2- (log beta11(Pb)=12.1(3)) compared to the lower value found for the one of the tripodal tpaa3- (log beta11(Pb)=10.0(1)) provides direct evidence of the influence of the stereochemically active lead lone pair on complex stability. As a result, since the ligand geometry has little effect on the stability of the calcium complex, a remarkable increase in the Pb/Ca selectivity is observed for dpaea-(10(6.6)) compared to tpaa3- (10(1.5)), making the dipodal ligand a good candidate for application as extracting agent for the lead removal from contaminated water.

SELECTION OF CITATIONS
SEARCH DETAIL
...